Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices

The Lancet

Volumn 388, Issue 10041, 2016, Pages 294-306

  Robinson, Bruce M ^a,b   Akizawa, Tadao ^c   Jager, Kitty J ^d   Kerr, Peter G ^e   Saran, Rajiv ^b   Pisoni, Ronald L ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASIA; CLINICAL DECISION MAKING; CLINICAL OUTCOME; CLINICAL PRACTICE; END STAGE RENAL DISEASE; EUROPE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEMODIALYSIS; HOME DIALYSIS; HOSPITAL CARE; HUMAN; INCIDENCE; JAPAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; MORTALITY; OVERALL SURVIVAL; PERSONAL EXPERIENCE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION; UNITED STATES; VASCULAR ACCESS; COMPARATIVE STUDY; KIDNEY FAILURE, CHRONIC; PROCEDURES; REGISTER; STATISTICS AND NUMERICAL DATA;

EUROPE; KIDNEY FAILURE, CHRONIC; REGISTRIES; RENAL DIALYSIS;

EID: 84982113886     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30448-2     Document Type: Review

References (116)

1. 1 Liyanage, T, Ninomiya, T, Jha, V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385 (2015), 1975–1982.
2. 2 US Renal Data System. 2015 USRDS Annual Data Report: epidemiology of kidney disease in the United States, vol 2, 2015, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
3. 3 Caskey, FJ, Kramer, A, Elliott, RF, et al. Global variation in renal replacement therapy for end-stage renal disease. Nephrol Dial Transplant 26 (2011), 2604–2610.
4. 4 van de Luijtgaarden, MW, Noordzij, M, van Biesen, W, et al. Conservative care in Europe–nephrologists' experience with the decision not to start renal replacement therapy. Nephrol Dial Transplant 28 (2013), 2604–2612.
5. 5 UK, NHS, End of life care in adavanced kidney disease: a framework for Implementation. http://www.ncpc.org.uk/sites/default/files/EndOfLifeCareInAdvancedKidneyDisease.pdf (accessed March 7, 2016).
6. 6 Watanabe, Y, Hirakata, H, Okada, K, et al. for the Japanese Society for Hemodialysis Therapy Guideline Commission of Maintenance Hemodialysis Investigation, Subgroup Commission on withholding and withdrawal from dialysis. Proposal for the shared decision-making process regarding initiation and continuation of maintenance hemodialysis. Ther Apher Dial 19:suppl 1 (2015), 108–117.
7. 7 The Renal Physicians Association. Shared decision-making in the appropriate initiation of and withdrawal from dialysis, second edition. http://www.thaddeuspope.com/images/RPA_-_2010_no_dialysis_PVS_or_dementia.pdf, 2010 (accessed March 7, 2016).
8. 8 Thomas, B, Wulf, S, Bikbov, B, et al. Maintenance dialysis throughout the world in years 1990 and 2010. J Am Soc Nephrol 26 (2015), 2621–2633.
9. 9 Combe, C, Albert, JM, Bragg-Gresham, JL, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 54 (2009), 680–692.
10. 10 Goodkin, DA, Bragg-Gresham, JL, Koenig, KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14 (2003), 3270–3277.
11. 11 Herrington, W, Haynes, R, Staplin, N, et al. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 28 (2015), 35–47.
12. 12 Pippias, M, Jager, KJ, Kramer, A, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant 31 (2016), 831–841.
13. 13 Thodis, ED, Oreopoulos, DG, Home dialysis first: a new paradigm for new ESRD patients. J Nephrol 24 (2011), 398–404.
14. 14 ERA-EDTA Registry. ERA-EDTA Registry annual report 2013, 2015, The European Renal Association–European Dialysis and Transplant Association, Amsterdam.
15. 15 Masakane, I, Nakai, S, Ogata, S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial 19 (2015), 540–574.
16. 16 ERA-EDTA Registry. ERA-EDTA Registry 2005 annual report, 2007, The European Renal Association–European Dialysis and Transplant Association, Amsterdam.
17. 17 Seng WH, Meng OL. Chapter 3: death and survival on dialysis. In: Goh BL, Ong LM, Lim YM, eds. 21st report of the Malaysian dialysis and transplant registry 2013. Kuala Lumpur, 2014.
18. 18 Wu, M-S, Wu, I-W, Hsu, K-H, Survival analysis of Taiwan renal registry data system (TWRDS) 2000–2009. Acta Nephrol 26 (2012), 104–108.
19. 19 Jha, V, John, O, Joshi, R, et al. Dialysis outcomes in India: a pilot study. Nephrology (Carlton) 20 (2015), 329–334.
20. 20 van Manen, JG, van Dijk, PC, Stel, VS, et al. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 22 (2007), 187–195.
21. 21 Yoshino, M, Kuhlmann, MK, Kotanko, P, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 17 (2006), 3510–3519.
22. 22 van Dijk, PC, Zwinderman, AH, Dekker, FW, et al. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 71 (2007), 53–59.
23. 23 Ueshima, H, Sekikawa, A, Miura, K, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118 (2008), 2702–2709.
24. 24 Roderick, P, Byrne, C, Casula, A, et al. Survival of patients from South Asian and Black populations starting renal replacement therapy in England and Wales. Nephrol Dial Transplant 24 (2009), 3774–3782.
25. 25 van den Beukel, TO, Dekker, FW, Siegert, CE, Increased survival of immigrant compared to native dialysis patients in an urban setting in the Netherlands. Nephrol Dial Transplant 23 (2008), 3571–3577.
26. 26 Robinson, BM, Joffe, MM, Pisoni, RL, Port, FK, Feldman, HI, Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 17 (2006), 2910–2918.
27. 27 Genovese, G, Friedman, DJ, Ross, MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329 (2010), 841–884.
28. 28 Kopp, JB, Nelson, GW, Sampath, K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22 (2011), 2129–2137.
29. 29 Rosset, S, Tzur, S, Behar, DM, Wasser, WG, Skorecki, K, The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol 7 (2011), 313–326.
30. 30 Kruzel-Davila, E, Wasser, WG, Aviram, S, Skorecki, K, APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol Dial Transplant 31 (2016), 349–358.
31. 31 Tentori, F, Wang, M, Bieber, BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS Study. Clin J Am Soc Nephrol 10 (2015), 98–109.
32. 32 Bailie, GR, Larkina, M, Goodkin, DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 87 (2015), 162–168.
33. 33 Robinson, B, Zhang, J, Morgenstern, H, et al. Worldwide, mortality is a high risk soon after initiation of hemodialysis. Kidney Int 85 (2014), 158–165.
34. 34 Asano, M, Thumma, J, Oguchi, K, et al. Vascular access care and treatment practices associated with outcomes of arteriovenous fistula: International comparisons from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract 124 (2013), 23–30.
35. 35 Tentori, F, Zhang, J, Li, Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the DOPPS. Nephrol Dial Transplant 27 (2012), 4180–4188.
36. 36 Robinson, BM, Bieber, B, Pisoni, RL, Port, FK, Public policy series. Dialysis Outcomes and Practice Patterns Study (DOPPS): its strengths, limitations, and role in informing practices and policies. Clin J Am Soc Nephrol 7 (2012), 1897–1905.
37. 37 Robinson, B, Tong, L, Zhang, J, et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 82 (2012), 570–580.
38. 38 Lopes, AA, Tong, L, Thumma, J, et al. Phosphate binder use and mortality among hemodialysis patients in the DOPPS: evaluation of possible confounding by nutritional status. Am J Kidney Dis 60 (2012), 90–101.
39. 39 Jadoul, M, Thumma, J, Fuller, DS, et al. Modifiable practices associated with sudden death among hemodialysis (HD) patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 7 (2012), 765–774.
40. 40 Zhang, H, Schaubel, DE, Kalbfleisch, JD, et al. Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. Kidney Int 81 (2012), 1108–1115.
41. 41 Hecking, M, Karaboyas, A, Saran, R, et al. Dialysate sodium concentration and the association with interdialytic weight gain, hospitalization, and mortality. Clin J Am Soc Nephrol 7 (2012), 92–100.
42. 42 Pisoni, RL, Arrington, CJ, Albert, JM, et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am J Kidney Dis 53 (2009), 475–491.
43. 43 Ramirez, SP, Albert, JM, Blayney, MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 20 (2009), 1094–1101.
44. 44 Lopes, AA, Bragg-Gresham, JL, Ramirez, SPB, et al. Prescription of antihypertensive agents to hemodialysis patients: time trends and associations with patient characteristics, country, and survival in the DOPPS. Nephrol Dial Transplant 24 (2009), 2809–2816.
45. 45 Hasegawa, T, Bragg-Gresham, JL, Yamazaki, S, et al. Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol 4 (2009), 595–602.
46. 46 Mendelssohn, DC, Pisoni, RL, Arrington, CJ, et al. A practice-related risk score (PRS): a DOPPS-derived aggregate quality index for haemodialysis facilities. Nephrol Dial Transplant 23 (2008), 3227–3233.
47. 47 Tentori, F, Blayney, MJ, Albert, JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52 (2008), 519–530.
48. 48 Saran, R, Elder, SJ, Goodkin, DA, et al. Enhanced training in vascular access creation predicts arteriovenous fistula placement and patency in hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study. Ann Surg 247 (2008), 885–891.
49. 49 Port, FK, Practice-based versus patient-level outcomes research in hemodialysis: the DOPPS (Dialysis Outcomes and Practice Patterns Study) experience. Am J Kidney Dis 64 (2014), 969–977.
50. 50 Port, FK, Wolfe, RA, Hulbert-Shearon, TE, Ashby, VB, McCullough, KP, Held, PJ, High dialysis dose is associated with lower mortality among women but not among men. Am J Kidney Dis 43 (2004), 1014–1023.
51. 51 Mapes, DL, Lopes, AA, Satayathum, S, et al. Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64 (2003), 339–349.
52. 52 Pisoni, RL, Young, EW, Dykstra, DM, et al. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61 (2002), 305–316.
53. 53 Young, EW, Goodkin, DA, Mapes, DL, et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 57 (2000), S74–S81.
54. 54 Pisoni, RL, Gillespie, BW, Dickinson, DM, Chen, K, Kutner, MH, Wolfe, RA, The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44 (2004), 7–15.
55. 55 Port, FK, Wolfe, RA, Held, PJ, Young, EW, Random sample (DOPPS) versus census-based registry approaches to kidney disease research. Blood Purif 21 (2003), 85–88.
56. 56 Hecking, M, Karaboyas, A, Saran, R, et al. Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 59 (2012), 238–248.
57. 57 Fuller, DS, Bieber, BA, Pisoni, RL, et al. International comparisons to assess effects of payment and regulatory changes in the United States on anemia practice in patients on hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol, 2015 published online Nov 18. 10.1681/ASN.2015060673.
58. 58 Hasegawa, T, Bragg-Gresham, JL, Pisoni, RL, et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 79 (2011), 340–346.
59. 59 Sehulster, L, Chinn, RY US Centers for Disease Control and Prevention, Healthcare Infection Control Practices Advisory Committee. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52 (2003), 1–42.
60. 60 Kelley-Hedgepeth, A, Lloyd-Jones, DM, et al. Ethnic differences in C-reactive protein concentrations. Clin Chem 54 (2008), 1027–1037.
61. 61 Inrig, JK, Califf, RM, Tasneem, A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 63 (2014), 771–780.
62. 62 Astor, BC, Eustace, JA, Powe, NR, Klag, MJ, Fink, NE, Coresh, J, CHOICE study. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study. J Am Soc Nephrol 16 (2005), 1449–1455.
63. 63 Bradbury, BD, Chen, F, Furniss, A, et al. Conversion of vascular access type among incident hemodialysis patients: description and association with mortality. Am J Kidney Dis 53 (2009), 804–814.
64. 64 Xue, JL, Dahl, D, Ebben, JP, Collins, AJ, The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 42 (2003), 1013–1019.
65. 65 Polkinghorne, KR, McDonald, SP, Atkins, RC, Kerr, PG, Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 15 (2004), 477–486.
66. 66 Allon, M, Daugirdas, J, Depner, TA, Greene, T, Ornt, D, Schwab, SJ, Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 47 (2006), 469–477.
67. 67 Lacson, E Jr, Wang, W, Hakim, RM, Teng, M, Lazarus, JM, Associates of mortality and hospitalization in hemodialysis: Potentially actionable laboratory variables and vascular access. Am J Kidney Dis 53 (2009), 79–90.
68. 68 Engemann, JJ, Friedman, JY, Reed, SD, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 26 (2005), 534–539.
69. 69 Lee, H, Manns, B, Taub, K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 40 (2002), 611–622.
70. 70 Pisoni, RL, Zepel, L, Port, FK, Robinson, BM, Trends in US vascular access use, patient preferences, and related practices: an update from the US DOPPS practice monitor with international comparisons. Am J Kidney Dis 65 (2015), 905–915.
71. 71 Bikbov BT, Tomilina NA. Renal replacement therapy for ESRD patients in Russian Federation, 1998–2013. Report of Russian RRT registry. Part 2. Nephrol Dial (in press).
72. 72 US Centers for Medicare & Medicaid Services. Technical specifications for ESRD QIP measures. www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/061_TechnicalSpecifications.html (accessed March 4, 2016).
73. 73 Vassalotti, JA, Jennings, WC, Beathard, GA, et al. Fistula first breakthrough initiative community education committee (2012) fistula first breakthrough initiative: targeting catheter last in fistula first. Semin Dial 25 (2012), 303–310.
74. 74 National Kidney Foundation. The National Kidney Foundation kidney disease outcomes quality initiative, 2006. Vascular access guidelines. http://www.kidney.org/professionals/kdoqi/pdf/12-50-0210_JAG_DCP_Guidelines-VA_Oct06_SectionC_ofC.pdf (accessed July 23, 2013).
75. 75 Kumwenda, M, Mitra, S, Reid, C, Clinical practice guideline: vascular access for haemodialysis, 2015, UK Renal Association, Hampshire.
76. 76 The Japanese Society for Dialysis Therapy. Guidelines pertaining to creating and repairing vascular access for chronic hemodialysis. J Jpn Soc Dial Ther 44 (2011), 855–937.
77. 77 Rayner, HC, Pisoni, RL, The increasing use of hemodialysis catheters: evidence from the DOPPS on its significance and ways to reverse it. Semin Dial 23 (2010), 6–10.
78. 78 UK NHS Department of Health. Payment by results guidance for 2011–12. http://webarchive.nationalarchives.gov.uk/20130402234253/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_126157.pdf (accessed March 8, 2016).
79. 79 Abma, I, Jayanti, A, Bayer, S, et al. Perceptions and experiences of financial incentives: a qualitative study of dialysis care in England. BMJ Open, 4, 2014, e004249.
80. 80 Fistula First: Fistula first national vascular access improvement initiative. http://www.fistulafirst.org (accessed March 4, 2016).
81. 81 Fissell, RB, Fuller, DS, Morgenstern, H, et al. Hemodialysis patient preference for type of vascular access: variation and predictors across countries in the DOPPS. J Vasc Access 14 (2013), 264–272.
82. 82 Pisoni, R, Zepel, L, Tentori, F, et al. International variability in arteriovenous fistula maturation and placement: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 26 (2015), 285A–286A.
83. 83 Lok, CE, McCullough, K, Fluck, RJ, et al. Rising vascular access (VA) procedure rates over time internationally: findings from the DOPPS. J Am Soc Nephrol, 23, 2012, 268A.
84. 84 Owen, WF Jr, Lew, NL, Liu, Y, Lowrie, EG, Lazarus, JM, The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329 (1993), 1001–1006.
85. 85 Depner, T, Daugirdis, J, Greene, T, et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 65 (2004), 1386–1394.
86. 86 McIntyre, CW, Burton, JO, Selby, NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3 (2008), 19–26.
87. 87 Ok, E, Asci, G, Chazot, C, Ozkahya, M, Dorhout Mees, EJ, Dialysis 2. Controversies and problems of volume control and hypertension in haemodialysis. Lancet, 2016 published online May 22. 10.1016/S0140-6736(16)30389-0.
88. 88 Flythe, JE, Curhan, GC, Brunelli, SM, Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 83 (2013), 104–113.
89. 89 Brunelli, SM, Chertow, GM, Ankers, ED, Lowrie, EG, Thadhani, R, Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. Kidney Int 77 (2010), 630–636.
90. 90 Daugirdas, JT, Dialysis time, survival, and dose-targeting bias. Kidney Int 83 (2013), 9–13.
91. 91 Kleophas, W, Karaboyas, A, Li, Y, et al. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kidney Int 84 (2013), 578–584.
92. 92 Watanabe, Y, Kawanishi, H, Suzuki, K, Japanese Society for Hemodialysis therapy clinical guideline for proposal for “Maintenance Hemodialysis; Hemodialysis Prescriptions”. Ther Apher Dial 19:suppl 1 (2015), 67–92.
93. 93 FHN Trial Group, Chertow, GM, Levin, NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 363 (2010), 2287–2300.
94. 94 Culleton, BF, Walsh, M, Klarenbach, SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298 (2007), 1291–1299.
95. 95 Nesrallah, GE, Lindsay, RM, Cuerden, MS, et al. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol 23 (2012), 696–705.
96. 96 Marshall, MR, Hawley, CM, Kerr, PG, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis 58 (2011), 782–793.
97. 97 Rocco, MV, Daugirdas, JT, Greene, T, et al., for the FHN Trial Group. Long-term effects of frequent nocturnal hemodialysis on mortality: the Frequent Hemodialysis Network (FHN) Nocturnal Trial. Am J Kidney Dis 66 (2015), 459–468.
98. 98 Rocco, MV, Lockridge, RS Jr, Beck, GJ, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 80 (2011), 1080–1091.
99. 99 Foley, RN, Gilbertson, DT, Murray, T, Collins, AJ, Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med 365 (2011), 1099–1107.
100. 100 ANZDATA Registry. Chapter 4: haemodialysis. In: The 37th annual ANZDATA report, 2014, Australia and New Zealand Dialysis and Transplant Registry, Adelaide.
101. 101 Kalantar-Zadeh, K, Unruh, M, Zager, PG, et al. Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. Am J Kidney Dis 64 (2014), 181–186.
102. 102 Bieber, B, Qian, J, Anand, S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics, and quality of life in the China Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 29 (2014), 1770–1777.
103. 103 Bradbury, BD, Fissell, RB, Albert, JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2 (2007), 89–99.
104. 104 Foley, RN, Chen, SC, Solid, CA, Gilbertson, DT, Collins, AJ, Early mortality in patients starting dialysis appears to go unregistered. Kidney Int 86 (2014), 392–398.
105. 105 Gillespie, BW, Morgenstern, H, Hedgeman, E, et al. Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA. Clin Kidney J 8 (2015), 772–780.
106. 106 Watanabe, Y, Yamagata, K, Nishi, S, et al. Japanese Society for Dialysis therapy clinical guideline for “Hemodialysis Initiation for Maintenance Hemodialysis”. Ther Apher Dial 19 (2015), 93–107.
107. 107 Allon, M, Dinwiddie, L, Lacson, E Jr, et al. Medicare reimbursement policies and hemodialysis vascular access outcomes: a need for change. J Am Soc Nephrol 22 (2011), 426–430.
108. 108 Cooper, BA, Branley, P, Bulfone, L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363 (2010), 609–619.
109. 109 Crews, DC, Scialla, JJ, Liu, J, et al. Predialysis health, dialysis timing, and outcomes among older United States adults. J Am Soc Nephrol 25 (2014), 370–379.
110. 110 Crews, DC, Scialla, JJ, Boulware, LE, et al. Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD. Am J Kidney Dis 63 (2014), 806–815.
111. 111 Mehrotra, R, Rivara, M, Himmelfarb, J, Initiation of dialysis should be timely: neither early nor late. Semin Dial 26 (2013), 644–649.
112. 112 NKF-DOQI clinical practice guidelines for peritoneal dialysis adequacy. National Kidney Foundation. Am J Kidney Dis 30:3 suppl 2 (1997), S67–136.
113. 113 US Renal Data System. USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2010, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
114. 114 Lacson, E Jr, Wang, W, DeVries, C, et al. “Effects of a nationwide predialysis educational program on modality choice, vascular access, and patient outcomes.”. Am J Kidney Dis 58 (2011), 235–242.
115. 115 National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 66 (2015), 884–930.
116. 116 Remuzzi, G, Benigni, A, Finkelstein, FO, et al. Kidney failure: aims for the next 10 years and barriers to success. Lancet 382 (2013), 353–362.